Related Experiment Video
Updated: May 14, 2026
06:08
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
Published on: March 11, 2017
Update on tamper-resistant drug formulations.
M K Romach1, K A Schoedel, E M Sellers
1DL Global Partners Inc., Toronto, ON, Canada. m.romach@dlglobalpartners.com
Drug and Alcohol Dependence
|February 19, 2013
Summary
Drug formulation significantly impacts prescription medication abuse risk. Developing abuse-deterrent formulations requires public health support and regulatory encouragement to become the standard of care.
Area of Science:
- Pharmacology
- Public Health
- Drug Development
Background:
- A 2005 expert panel identified drug formulation as key to reducing prescription medication abuse.
- Pharmaceutical companies are developing opioid formulations resistant to tampering (e.g., crushing, dissolving).
- Regulatory bodies like the US FDA require extensive postmarketing data for abuse-deterrent label claims.
Purpose of the Study:
- To review progress in abuse-deterrent opioid formulations since 2005.
- To discuss the impact of these formulations on both abusers and compliant patients.
- To highlight the need for public health and regulatory support for abuse-deterrent products.
Main Methods:
- Literature review using PubMed (2000-2011).
- Inclusion of scientific work presented by authors and colleagues through May 2012.
- Focus on opioid formulations and abuse deterrence strategies.
Main Results:
- Several tamper-resistant opioid formulations have been approved.
- The FDA has not yet approved explicit abuse-deterrent label claims.
- The impact on compliant patients versus those who abuse medication is an ongoing question.
Conclusions:
- Development of abuse-deterrent products needs broad public health support.
- Continued regulatory encouragement is vital for these products to become standard care.
- Abuse-deterrent formulations represent a significant area of advancement in medication safety.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:16Drug Product Stability
The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...